Skip to main menu Skip to main content Skip to footer

Robert B. Pendleton, M.D., Ph.D

"Since opening my practice 25 years ago I have had one goal: to provide individualized care to my patients and help them see their best and live life to the fullest."

Robert Pendleton Opthalmologist Headshot


Request an Appointment Locations

Medical Director

Native to the San Diego area, Dr. Pendleton graduated from La Jolla High School in 1977 and attended college at the University of California, Davis. Always seeking the path least traveled, he spent his Junior year at the University of Lund, Sweden. In 1981 Dr. Pendleton graduated with Honors in biochemistry and entered the graduate program in chemistry. In 1982 he left Davis with a Master of Science degree in Physical Chemistry, and he entered the MD/PhD program at the University of Illinois at Urbana-Champaign.

Eight long years later, including a move up to Chicago, Dr. Pendleton graduated with a PhD in biochemistry from the University of Illinois at Urbana-Champaign and an MD from the University of Illinois at Chicago. In Chicago, he served as President of the Alpha Chapter of the honors medical society, Alpha Omega Alpha (AOA), and at graduation, he received the William J Grove Outstanding Medical Student Award, given to one student each year for outstanding scholarship and community involvement.

Dr. Pendleton attended a one year Internal Medicine Residency at Northwestern University School of Medicine in Chicago, followed by a three year Ophthalmology Residency, also at Northwestern. At Northwestern he was the first resident to perform refractive surgery (astigmatic keratotomy).

On July 15th, 1994,  Dr. Pendleton officially began private practice in a busy surgical practice in Buffalo, New York, where he specialized in cataract surgery, refractive surgery and corneal transplants. In September of 1996, he continued to refine his No Stitch, No Patch, No Injection cataract surgery technique in Minneapolis and the Brainerd Lakes area of Minnesota. That office had one of the first excimer lasers and it was there that Dr. Pendleton began to perform laser refractive surgery.

Tired of the hostile weather, and not terribly interested in ice fishing, in August of 1997 Dr. Pendleton returned to sunny San Diego, and in 1998 opened the doors to the Pendleton Eye Center.

  • College
    – Bachelor of Science, Biochemistry, University of California at Davis, Davis, California (1977 – 1981)
    – Master of Science Physical Chemistry, University of California at Davis (1982 – 1981)
    – Ph.D. in Biochemistry, University of Illinois at Urbana-Champaign (1982 – 1990
  • Medical School
    Doctor of Medicine, University of Illinois at Chicago (1984 – 1990)
  • Internship
    Internal Medicine Internship, Northwestern University School of Medicine (1990 – 1991)
  • Residency
    Northwestern University School of Medicine, Ophthalmology (1991 – 1994)

  • Board Certification American Board of Ophthalmology
  • American Society of Cataract and Refractive Surgeons
    (1984 – Present)
  • California Medical Association (2002 – Present)
  • Surgical Eye Expeditions (2004 – Present)
  • Carlsbad Rotary (2004 – 2009)
  • Flying Samaritans (1998 – 2004)
  • University of California at San Diego Department of Ophthalmology Attending of the Year (2001)
  • University of Illinois William J. Grove Outstanding Medical Student (1990)
  • National Dean’s List (1990)
  • Alpha Omega Honor Medical Society (1987)
  • Phi Lamda Upsilon Honor Chemistry Society (1983)

Kulmacz RJ, Pendleton RB, Lands WEM. Interaction between Peroxidase and Cyclooxygenase Activities in Prostaglandin Endoperoxide Synthase: Interpretation of Reaction Kinetics. J Biol Chem 1994;269(8):5527-5536

Stock IL, Pendleton RB. Pharmacological Treatment of Ocular Allergic Diseases. Int Ophth Clin 1993;33(4):47-58

Pendleton RB, Lands WEM. Kinetic Basis of the Impaired Oxygenation of Eicosapentaenoate by Prostaglandin Endoperoxide Synthase. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury (Honn, Marnett, Nigam, and Walden, eds). Kluwer Acad Pub, Boston 1991:209-212

Cramer GL, Miller Jr JF, Pendleton RB, Lands WEM. lodometric Measurement of Lipid Hydroperoxides in Human Plasma. Anal Biochem 1991;193:204-211

Kulmacz RJ, Miller Jr JF, Pendleton RB, Lands WEM. Cyclooxygenase Initiation Assay for Hydroperoxides. Meth Enzymol 1990;186:431-438

Pendleton RB. Hydroperoxide Stimulation of Prostaglandin Endoperoxide Synthase. Doctoral Thesis, University of Illinois, Urbana-Champaign 1990

Lands WEM, Pendleton RB. n-3 Fatty Acids and Hydroperoxide Activation of Fatty Acid Oxygenases. In: Oxygen Radicals in biology and Medicine (Simic, Ward, and Taylor, eds). Plenum Pub Corp 1989:675-681

Lands WEM, Pendleton RB. Amplification of Tissue Peroxides in Disease. In: Anticarcinogenesis and Radiation Protection (Cerutti, Nygaard, Simic, eds). Plenum Pub Corp 1987:81-84

Pendleton RB, Lands WEM. Assay of Lipid Hydroperoxides by Activation of Cyclooxygenase Activity. Free Radical Biol Med 1987;3:337-339

Pendleton RB. Macroencapsulation in Covalently Stabilized Calcium-Alginate: A Feasibility Demonstration of a New Immobilization Technique. Master’s Thesis, University of Calif., Davis 1982

Birnbaum S, Pendleton R. Larsson PO, Mosbach K. Covalent Stabilization of Alginate Gel for the Entrapment of Living Whole Cells. Bioltech Let 1981:3:393-400

Kulmacz RJ, Pendleton RB, and Lands WEM. Mechanistic Model for Prostaglandin Endoperoxide Synthase Kinetics. Prostaglandins and Related Compounds, Florence, Italy. May 1990

Pendleton RB. Eicosapentaenoate Differs from Arachidonate in Amplifying Hydroperoxide Activators. Eicosanoids and Bioactive Lipids in Cancer and Radiation Injury. Detroit, Ml. October 1989

Pendleton RB, Lands WEM. Eicosapentaenoate Causes Impaired Hydroperoxide Amplification of Prostaglandin Synthase. Midwest Enzyme Chemistry Conference, Chicago, IL. September 1987


Principal Investigator:

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-120 I in the Treatment of Acquired Blepharoptosis (Study RVL-1201-202/203) June 2018 – May 2019.

A Phase 3, Double-Masked, Randomized, Controlled Study of KPl-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease. Protocol: KPl-121-C-006. August 2016 – January 2018

Dry Eye Assessment and Management (DREAM): A double masked randomized clinical trial, to test an omega-3 fatty acids supplement as a treatment for dry eye symptoms. Funding Source: National Eye Institute/NIH Grants U10 EY022881 and U10 EY022879. October 2014 – Present, December 2017

A Phase 3, Double-Masked, Randomized. Controlled Study to Evaluate the Safety and Efficacy of KPl-121 1.0% Ophthalmic Suspension in Subjects with Postsurgical Inflammation and Pain Protocol Number: KPl-121-C-005. September 2016 – April 2017

A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunoda)Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension – APOLLO Study February 2013- August 2015

A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38%(BID and TIO) versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery; January 2014 – July 2014

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis; November 2012- August 2013

A study to Evaluate the Safety and Efficacy of AGN-195263 (0.01%, 0.03%, and 0.1%) Ophthalmic Emulsion Twice Daily Ocular Topical Administration Compared to Vehicle in Patients with Meibomian Gland Dysfunction (MGD); July 2012-Dec 2013

Principal Investigator:

A Phase 3, Multicenter, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in subjects for the Treatment of Ocular Inflammation Following Cataract Surgery; July 2012- June 2013

A Phases 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a(PEG, Pegasys*) and Ribavirin (RBV, Copegus*) With and without Tegbuvir (GS-9190) Followed by Virus Infection (Protocol GS-US-196-0140); May 2011-September 2012

A Study to evaluate the safety of Besivance (besifloxacin ophthalmic suspension) 0.6% compared to vehicle following TIO dosing for 7 days; June 2010-November 2011

Evaluation of Loptepredonl Etabonate Ophthalmic Gel 0.5% versus vechicle for treatment of inflammation and pain following cataract surgery; January 2010- August 2010

A Randomized Double Masked Study of AL38583 0.5% Opthalmic Solution for the Treatment of Dry Eye: May 2009-January 2010

Moxifloxacin AF 0.5% Ophthalmic Solution for the Treatment of Bacterial Conjunctivitis Study; April 2009-February 2010

A Clinical Safety and Efficacy Evaluation of Zylet Compared to Lotemax for the Treatment of Blepharoconjunctivitis in Pediatric Subjects; June 2008- March 2010

An Evaluation of the Ocular Surface Health in Subjects Using Travatan Z Opthalmic Solution Versus Yalatan Ophthalmic Solution; September 2008- June 2009

An Evaluation of the Safety and Efficacy of Lubricant Eye Drops FID 112903; April 2008-September 2008

Dosage Determination of Hyroxypropyl Guar Galactomannan (HPGG) in Dry Eye Patients; November 2007-January 2008

An Evaluation of the Safety and Efficacy of Systane Free FID 105783; June 2006-November 2006

A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis; February 2006- August 2007


Sub Investigator:

Phase Ill, Multi-Center, Randomized, 24-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominate negative Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 28 Week Double­ Blind Treatment Period; March 2012-2014

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study of Cariprazine (RGH-188) in the prevention of Relapse in Patients with Schizophrenia; October 2011-2013

Phase Ill, Multi-Center, Randomized, 12-week Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-Optimally Controlled

Symptoms of Schizophrenia Treated with Antipsychotics Followed by a 40 Week Double-Blind, Parallel-Group Placebo-Controlled Treatment Period; March 2010 – 2012

A Double-Blind, Placebo and active controlled evaluation of the safety and efficacy of Cariprazine in the acute exacerbation of Schizophrenia; March 2010 – September 2011

Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study; October 2008 – January 2010

A four-week randomized, Double-blind parallel group placebo controlled study to investigate the safety and efficacy of EVT101 as monotherapy in patients with treatment-resistant major depression; March 2010 – May 2011

A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the safety and efficacy of Two doses of Lurasidone HCL in Acutely Psychotic Patients with Schizophrenia; May 2008 – January 2010

Dr. Pendleton’s Patient Reviews

patient portal
Optical Shop
(760) 758-2008


Serving North San Diego County


3637 Vista Way
Oceanside, CA 92056

(760) 758-2008 Map of Our Location